Hypercholesterolemia, characterized by increased plasma low-density lipoprotein cholesterol, is a major determinant of the risk of cardiovascular disease (the leading cause of global mortality). Unfortunately, the commonly known cholesterol-lowering drugs are not effective enough to obtain the recommended cholesterol levels for many people. PCSK9 plays a critical role in cholesterol metabolism, and thus its inhibition emerged as a novel therapeutic target for hypercholesterolemia.
Whether it is for research, development or diagnostics, life sciences typically require the quantitation and characterization of samples with assays that classically measure molecules one at a time. Considering that the development and execution of such assays are time consuming and requires considerable investment, the uses of multiplexed analysis would be highly advantageous. Mass spectrometry is a technology that allows multiplexing, but requires highly specialized knowledge in order to achieve the desired results.
Join a thriving innovation ecosystem. Subscribe now